Literature DB >> 34817687

Time-course of decline in different cognitive domains in Parkinson's disease: a retrospective study.

Christian F Altmann1, Kristian Trubelja2, David Emmans3, Wolfgang H Jost3,4.   

Abstract

Cognitive impairment and dementia are common non-motor symptoms in Parkinson's disease (PD). To elucidate the potentially typical progression of cognitive decline in PD and its variation, we retrospectively surveyed neuropsychological data obtained at the Parkinson-Klinik Ortenau, Germany in the years 1996-2015. Many of the patients in the surveyed period were repeatedly admitted to our clinic and we were thus able to compile neuropsychological re-test data for 252 patients obtained at varying time intervals. Neuropsychological testing was conducted with the NAI (Nürnberger Alters-Inventar). This battery provides sub-tests that examine cognitive processing speed, executive function, working memory, and verbal/visual memory functions. The re-test time span varied across patients from below 1 year up to about 12 years. Most patients were seen twice, but some patients were tested up to eight times. The steepest rates of cognitive decline were observed for the NAI sub-tests Trail-Making, Maze Test, and Stroop-Word Reading/Color Naming. Intermediate rates of decline were found for Digit Span, Word List-Immediate Recall, and Picture Test. Stroop Test-Interference, Word List-Delayed Recognition, and Figure Test exhibited the slowest decline rates. We did not observe a significant effect of age at diagnosis or gender on the rate of decline. In sum, this study retrospectively evaluated cognitive decline in a sample of patients with PD. Our data suggest a broad cognitive decline that particularly affects the cognitive capacities for processing speed, executive functions, and immediate memory functions.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.

Entities:  

Keywords:  Attention; Cognitive impairment; Dementia; Executive functions; Memory; Parkinson’s disease

Mesh:

Year:  2021        PMID: 34817687     DOI: 10.1007/s00702-021-02441-w

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.850


  37 in total

1.  Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease.

Authors:  Jennifer G Goldman; Samantha Holden; Bryan Bernard; Bichun Ouyang; Christopher G Goetz; Glenn T Stebbins
Journal:  Mov Disord       Date:  2013-10-09       Impact factor: 10.338

Review 2.  Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data.

Authors:  A Cnaan; N M Laird; P Slasor
Journal:  Stat Med       Date:  1997-10-30       Impact factor: 2.373

3.  Longitudinal changes in adolescent risk-taking: a comprehensive study of neural responses to rewards, pubertal development, and risk-taking behavior.

Authors:  Barbara R Braams; Anna C K van Duijvenvoorde; Jiska S Peper; Eveline A Crone
Journal:  J Neurosci       Date:  2015-05-06       Impact factor: 6.167

Review 4.  Statistical Approaches to Longitudinal Data Analysis in Neurodegenerative Diseases: Huntington's Disease as a Model.

Authors:  Tanya P Garcia; Karen Marder
Journal:  Curr Neurol Neurosci Rep       Date:  2017-02       Impact factor: 5.081

Review 5.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Authors:  W R Gibb; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

6.  Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study.

Authors:  Murat Emre; Werner Poewe; Peter Paul De Deyn; Paolo Barone; Jaime Kulisevsky; Emmanuelle Pourcher; Teus van Laar; Alexander Storch; Federico Micheli; David Burn; Frank Durif; Rajesh Pahwa; Francesca Callegari; Nadia Tenenbaum; Christine Strohmaier
Journal:  Clin Neuropharmacol       Date:  2014 Jan-Feb       Impact factor: 1.592

Review 7.  Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force.

Authors:  Bruno Dubois; David Burn; Christopher Goetz; Dag Aarsland; Richard G Brown; Gerald A Broe; Dennis Dickson; Charles Duyckaerts; Jefferey Cummings; Serge Gauthier; Amos Korczyn; Andrew Lees; Richard Levy; Irene Litvan; Yoshikuni Mizuno; Ian G McKeith; C Warren Olanow; Werner Poewe; Cristina Sampaio; Eduardo Tolosa; Murat Emre
Journal:  Mov Disord       Date:  2007-12       Impact factor: 10.338

8.  Association of cognitive activities of daily living (ADL) function and nonmotor burden in nondemented Parkinson's disease patients.

Authors:  Sara Becker; Alena Bäumer; Walter Maetzler; Susanne Nussbaum; Zuzanna Tkaczynska; Patricia Sulzer; Maarten Timmers; Luc Van Nueten; Giacomo Salvadore; Kathrin Brockmann; Johannes Streffer; Daniela Berg; Inga Liepelt-Scarfone
Journal:  Neuropsychology       Date:  2020-03-19       Impact factor: 3.295

9.  Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

Authors:  Dag Aarsland; Kjeld Andersen; Jan P Larsen; Anette Lolk; Per Kragh-Sørensen
Journal:  Arch Neurol       Date:  2003-03

Review 10.  Clinical diagnostic criteria for dementia associated with Parkinson's disease.

Authors:  Murat Emre; Dag Aarsland; Richard Brown; David J Burn; Charles Duyckaerts; Yoshikino Mizuno; Gerald Anthony Broe; Jeffrey Cummings; Dennis W Dickson; Serge Gauthier; Jennifer Goldman; Christopher Goetz; Amos Korczyn; Andrew Lees; Richard Levy; Irene Litvan; Ian McKeith; Warren Olanow; Werner Poewe; Niall Quinn; Christina Sampaio; Eduardo Tolosa; Bruno Dubois
Journal:  Mov Disord       Date:  2007-09-15       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.